Healing, Lidocaine, Mebo, Traumatic Oral Ulceration
Conditions
Brief summary
This study aims to assess topical MEBO application on pain relief and wound healing.
Detailed description
One of the conditions that affect the mouth frequently is a traumatic ulcer. Between 3 and 24 % of the population are affected, which is a significant prevalence. It is symptomatic to treat traumatized ulcers. Oral wound healing is a dynamic process and complicated phenomenon involving secondary concerns, a succession of overlapping stages of rebuilding cell and tissue structure. Inflammation, granulation tissue creation, matrix formation, re-epithelialization, and tissue remodeling are some of the cellular and physiological activities that occur during wound healing. Oral wound healing is a dynamic process and complex phenomenon involving secondary issues, series overlapping stages of restoring tissue and cellular structures. Since 1995, the Moist Exposed Burn Ointment (MEBO), a Chinese burn ointment, has had a recognized US patent. Beta-sitosterol, Phellodendron amurense, Scutellaria baicalensis, Coptis chinensis, Pheretima aspergillum, Beeswax, and sesame oil are all natural ingredients found in MEBO, a pure herbal extract.
Interventions
DRUGMEBO
MEBO (Julphar®, Ras Al Khaimah, United Arab Emirates) was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
DRUGLidocaine
Lidocaine gel was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
Sponsors
October 6 University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Age from 20 to 50 years. * Both sexes. * Systemically healthy patients. * Patients with good oral hygiene.
Exclusion criteria
* Patients with any uncontrolled local or systemic disease. * Smokers. * Pregnancy and lactation. * Patients allergic to the used agents.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The degree of pain | 10 days after surgery | Pain score was reported by the patient directly through Visual Analogue Scale (VAS) score (between 0 and 10; 0: no pain, 1:minimal pain, 5: moderate pain, and 10: severe pain) VAS was recorded daily for 1 week. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Wound Size | 10 days after surgery | Wound size was measured using (UNC-15) periodontal probe. Wound size was measured at baseline and on days 2, 5, and 10. |
| The degree of re-epithelization | 10 days after surgery | Cytological analysis was performed using the superficial epithelial cell index indices at 2, 5 and 10 days. Superficial cell index = Cells with or without pyknotic nuclei / Total no. of examined cells x100 |
| The degree of keratinization | 10 days after surgery | Cytological analysis was performed using keratinization indices at 2, 5 and 10 days. Keratinization index = Cells without nuclei / Total no. of examined cells x100 |
Countries
Egypt
Outcome results
None listed